Using circulating cell-free DNA to monitor personalized cancer therapy

References

• Ashida A, Sakaizawa K, Mikoshiba A, Uhara H, Okuyama R. 2016. Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. Int J Clin Oncol. 21:981–988.
   PubMed Web of Science ®Google Scholar
• Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, et al. 2015. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 21:2315–2324.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, et al. 2009. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Beck J, Urnovitz HB, Mitchell WM, Schütz E. 2010. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res. 8:335–342.
   PubMed Web of Science ®Google Scholar
• Beck J, Urnovitz HB, Riggert J, Clerici M, Schütz E. 2009. Profile of the circulating DNA in apparently healthy individuals. Clin Chem. 55:730–738.
   PubMed Web of Science ®Google Scholar
• Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, Siu SS, Chan WC, Chan SL, Chan AT, et al. 2013. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. 59:211–224.
   PubMed Web of Science ®Google Scholar
• Coe TM, Fero KE, Fanta PT, Mallory RJ, Tang CM, Murphy JD, Sicklick JK. 2016. Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA. J Gastrointest Surg. 20:1132–1140.
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, et al. 2013. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 368:1199–1209.
   PubMed Web of Science ®Google Scholar
• Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, et al. 2017. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol. 71:680–687.
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, et al. 2005. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 102:16368–16373.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
   PubMed Web of Science ®Google Scholar
• FDA. Table of Pharmacogenomic Biomarkers in Drug Labeling [Internet]. Silver Spring (MD): U.S. Food and Drug Administration [cited 2016 Nov 22]. Available from: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
   Google Scholar
• Freidin MB, Freydina DV, Leung M, Montero Fernandez A, Nicholson AG, Lim E. 2015. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem. 61:1299–1304.
   PubMed Web of Science ®Google Scholar
• Gagan J, Van Allen EM. 2015. Next-generation sequencing to guide cancer therapy. Genome Med. 7:80.
   PubMed Web of Science ®Google Scholar
• Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, Shen L, Liu XY, Pao W, Chen H. 2010. Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas. J Thorac Oncol. 5:1130–1135.
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, et al. 2015. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 7:302ra133.
   PubMed Web of Science ®Google Scholar
• Grade M, Difilippantonio MJ, Camps J. 2015. Patterns of chromosomal aberrations in solid tumors. Recent Results Cancer Res. 200:115–142.
   PubMedGoogle Scholar
• Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, et al. 2013. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer. 133:346–356.
   PubMed Web of Science ®Google Scholar
• Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, Benezeder T, Auer M, Pischler C, Mannweiler S, et al. 2013. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 5:30.
   PubMed Web of Science ®Google Scholar
• ICGC. ICGC Cancer Genome Projects [Internet]. Ontario (ON): International Cancer Genome Consortium [cited 2016 Nov 10]. Available from: https://icgc.org/
   Google Scholar
• Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, et al. 2016. BRAF mutation testing in Cell-Free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Mol Cancer Ther. 15:1397–1404.
   Google Scholar
• Jorde LB, Carey JC, Bamshad MJ. 2010. Medical genetics. 4th ed. Philadelphia (PA): Mosby Elsevier.
   Google Scholar
• Koshiyama DB, Capra ME, Paskulin GA, Rosa RF, Oliveira CA, Vanelli T, Fogliatto LM, Zen PR. 2013. Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome. Ann Hematol. 92:185–189.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, et al. 2014. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 311:1998–2006.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Burton KA, Blau S, Rose AL, Parker S, Lyman GH, Blau CA. 2016. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol. DOI:10.1001/jamaoncol.2016.4983
   PubMedGoogle Scholar
• Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. 1999. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 64:218–224.
   PubMed Web of Science ®Google Scholar
• López SO, García-Olmo DC, García-Arranz M, Guadalajara H, Pastor C, García-Olmo D. 2016. KRAS G12V mutation detection by droplet digital PCR in circulating cell-free DNA of colorectal cancer patients. Int J Mol Sci. 17:484.
   PubMed Web of Science ®Google Scholar
• Machado MP, Tomaz JP, Lorand-Metze I, de Souza CA, Vigorito AC, Delamain MT, Bendit I, Pereira NF, Pagnano KB. 2011. Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase – the importance of a major molecular response. Rev Bras Hematol Hemoter. 33:211–215.
   PubMedGoogle Scholar
• Mao C, Yuan JQ, Yang ZY, Fu XH, Wu XY, Tang JL. 2015. Blood as a substitute for tumor tissue in detecting EGFR mutations for guiding EGFR TKIs treatment of nonsmall cell lung cancer: a systematic review and meta-analysis. Medicine (Baltimore). 94:e775.
   PubMed Web of Science ®Google Scholar
• Maus MV, Grupp SA, Porter DL, June CH. 2014. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 123:2625–2635.
   PubMed Web of Science ®Google Scholar
• McDermott U, Downing JR, Stratton MR. 2011. Genomics and the continuum of cancer care. N Engl J Med. 364:340–350.
   PubMed Web of Science ®Google Scholar
• Mouliere F, El Messaoudi S, Gongora C, Guedj AS, Robert B, Del Rio M, Molina F, Lamy PJ, Lopez-Crapez E, Mathonnet M, et al. 2013. Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl Oncol. 6:319–328.
   PubMed Web of Science ®Google Scholar
• Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, et al. 2013. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 497:108–112.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. The NCI dictionary of cancer terms [Internet]. Rockville (MD): National Cancer Institute at the National Institutes of Health [cited 2016 Nov 10]. Available from: www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=561717
   Google Scholar
• Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, et al. 2014. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 20:1698–1705.
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, et al. 2007. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 109:3496–3499.
   PubMed Web of Science ®Google Scholar
• Reck M, Hagiwara K, Han B, Tjulandin S, Grohe C, Yokoi T, Morabito A, Novello S, Arriola E, Molinier O, et al. 2016. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the assess study. J Thorac Oncol. 11:1682–1689.
   PubMed Web of Science ®Google Scholar
• Sandelin M, Berglund A, Sundström M, Micke P, Ekman S, Bergqvist M, Bergström S, Koyi H, Brandén E, Janson C, et al. 2015. Patients with non-small cell lung cancer analyzed for EGFR: adherence to guidelines, prevalence and outcome. Anticancer Res. 35:3979–3985.
   PubMed Web of Science ®Google Scholar
• Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, et al. 2016. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res. 22:567–574.
   PubMed Web of Science ®Google Scholar
• Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, et al. 2015. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 7:313ra182.
   PubMed Web of Science ®Google Scholar
• Schütz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, Mitchell WM, Nam RK, Narod SA. 2015. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem. 61:239–248.
   PubMed Web of Science ®Google Scholar
• Schütz E, Gummert J, Mohr F, Oellerich M. 1993. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 341:436.
   PubMed Web of Science ®Google Scholar
• Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, Chan WK, Ma ES, Chan SL, Cheng SH, et al. 2015. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci USA. 112:E5503–E5512.
   PubMed Web of Science ®Google Scholar
• Tannock IF, Hickman JA. 2016. Limits to personalized cancer medicine. N Engl J Med. 375:1289–1294.
   PubMed Web of Science ®Google Scholar
• Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et al. 2015. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 21:560–562.
   PubMed Web of Science ®Google Scholar
• Tie J, Gibbs P. 2016. Sequencing circulating cell-free DNA: the potential to refine precision cancer medicine. Clin Chem. 62:796–798.
   PubMed Web of Science ®Google Scholar
• Wang L, McLeod HL, Weinshilboum RM. 2011. Genomics and drug response. N Engl J Med. 364:1144–1153.
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, Barilla H, Cubello R, Sangal A, Whitehead RP, Kundranda M, Khemka V, et al. 2016. Abstract 3138: changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers [abstract]. Cancer Res. 76:abstr 3138.
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, Barilla H, Cubello R, Quan W, Waypa J, Sangal A, Khemka V, et al. 2016. Tumor cell-free DNA copy number instability (CNI) to predict therapeutic response to immunotherapy prior to cycle 2 [abstract]. J Clin Oncol. 34:abstr 3027.
   Google Scholar
• Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, Veal G, Astier A. 2014. Review of therapeutic drug monitoring of anticancer drugs part two-targeted therapies. Eur J Cancer. 50:2020–2036.
   PubMed Web of Science ®Google Scholar
• Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, et al. 2015. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 5:1040–1048.
   PubMed Web of Science ®Google Scholar
• Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. 2016. Current challenges in cancer treatment. Clin Ther. 38:1551–1566.
   PubMed Web of Science ®Google Scholar